S&P 500

5.431,60

-0,04%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Neumora Therapeutics Inc (NMRA)
Neumora Therapeutics Inc (NMRA) Notícias

NMRA

Neumora Therapeutics (NMRA)

Neumora Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:NMRA

1

Data	Hora	Fonte	Título	Código	Companhia
14/06/2024	17:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NMRA	Neumora Therapeutics Inc
14/06/2024	17:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NMRA	Neumora Therapeutics Inc
14/05/2024	08:00	GlobeNewswire Inc.	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	NASDAQ:NMRA	Neumora Therapeutics Inc
07/05/2024	17:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NMRA	Neumora Therapeutics Inc
07/05/2024	08:00	GlobeNewswire Inc.	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:NMRA	Neumora Therapeutics Inc
06/05/2024	08:00	GlobeNewswire Inc.	Neumora Therapeutics to Participate in Upcoming Conferences in May	NASDAQ:NMRA	Neumora Therapeutics Inc
15/04/2024	07:30	GlobeNewswire Inc.	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	NASDAQ:NMRA	Neumora Therapeutics Inc
13/03/2024	08:00	GlobeNewswire Inc.	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days	NASDAQ:NMRA	Neumora Therapeutics Inc
07/03/2024	18:34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NMRA	Neumora Therapeutics Inc
07/03/2024	09:00	GlobeNewswire Inc.	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:NMRA	Neumora Therapeutics Inc
22/01/2024	09:00	GlobeNewswire Inc.	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer	NASDAQ:NMRA	Neumora Therapeutics Inc
02/01/2024	09:00	GlobeNewswire Inc.	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:NMRA	Neumora Therapeutics Inc
15/12/2023	19:06	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:NMRA	Neumora Therapeutics Inc
12/12/2023	09:00	GlobeNewswire Inc.	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer	NASDAQ:NMRA	Neumora Therapeutics Inc
27/11/2023	09:00	GlobeNewswire Inc.	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study	NASDAQ:NMRA	Neumora Therapeutics Inc
01/11/2023	08:00	GlobeNewswire Inc.	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:NMRA	Neumora Therapeutics Inc
30/10/2023	08:00	GlobeNewswire Inc.	Neumora Therapeutics to Participate in Upcoming Conferences in November	NASDAQ:NMRA	Neumora Therapeutics Inc
10/10/2023	08:00	GlobeNewswire Inc.	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development	NASDAQ:NMRA	Neumora Therapeutics Inc
19/09/2023	19:51	KR Market News	인스타카트, 나스닥 데뷔로 주가는 12% 상승	NASDAQ:NMRA	Neumora Therapeutics Inc
14/09/2023	21:49	GlobeNewswire Inc.	Neumora Therapeutics Announces Pricing of Initial Public Offering	NASDAQ:NMRA	Neumora Therapeutics Inc